Chemistry:GSK1360707F

From HandWiki
Short description: Chemical compound
GSK1360707F
GSK1360707F.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC14H17Cl2NO
Molar mass286.20 g·mol−1
3D model (JSmol)
  (verify)

GSK1360707F is a potent and selective triple reuptake inhibitor.[1] It is chemically related to amitifadine and NS-2359 (GSK-372,475). Until recently,[when?] it was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.[citation needed]

Synthesis

Synthesis of GSK1360707F[2]
  1. BOC Protecting group.
  2. Enolization and trapping with triflate group (cf Comins' reagent).
  3. Suzuki reaction
  4. Reduction (only 1 mol eq. LAH because N-BOC can be reduced to N-Me)
  5. Trifluoroacetic acid (TFA) removal of protecting group.
  6. Simmons–Smith reaction cyclopropanation.
  7. Williamson ether synthesis (c.f. NS patents & paxil).

Transporter occupancy

GSK1360707F has recently (2013) been tested on baboons (Papio anubis) & humans for transporter occupancy using PET.[3]

See also

References

  1. "6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor". Journal of Medicinal Chemistry 53 (13): 4989–5001. July 2010. doi:10.1021/jm100481d. PMID 20527970. 
  2. Bertani, Barbara; Romano Di Fabio & Fabrizio Micheli et al., "Azabicyclic compounds as inhibitors of monoamines reuptake", WO patent 2008031772, published 2008-03-20
  3. "Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography". The Journal of Pharmacology and Experimental Therapeutics 346 (2): 311–7. August 2013. doi:10.1124/jpet.112.202895. PMID 23685546.